Cartesian Therapeutics, Inc. RNAC
7.41
(0.21)
(2.76%)
as of 25 Sep
- Market cap
- $230.6M
- P/E
- 0.0×
Follow RNAC
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
264.44% | 195.88% | 178.66% | 236.88% | |
| (11.21%) | (35.63%) | (43.52%) | (42.77%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(31.81%) | (102.99%) | (128.92%) | (104.80%) | |
Average Days of Receivables |
241.55 | 145.50 | 53.67 | 0.00 | |
Free Cash Flow per Share |
(2.64) | (3.06) | (2.88) | (2.67) | |
Free Cash Flow |
(68.55) | (79.39) | (77.37) | (78.61) | |
Capital Expenditures |
(5.32) | (5.45) | (4.41) | (2.08) | |
Piotroski F-Score |
1.00 | 1.00 | 1.00 | — | |
| Other line items | |||||
Cash ROIC |
(58.80%) | 6,715.80% | 247.54% | (101.73%) | |
Accounts Receivable Turnover |
0.33 | 2.82 | 1.75 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
5,009.26% | 2,074.87% | 3,539.32% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
2,782.58% | 1,125.06% | 1,705.18% | 0.00% | |
Share Based Compensation of Revenue |
938.77% | 376.15% | 587.94% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.36 | 0.57 | 0.48 | 0.51 | |
Depreciation/Fixed assets |
0.23 | 0.24 | 0.21 | 0.23 | |
Capex/Depreciation |
(1.87) | (1.84) | (1.82) | (0.80) | |
Revenue per Share |
0.04 | 0.11 | 0.07 | 0.00 | |
Operating CF per Share |
(2.43) | (2.85) | (2.72) | (2.60) | |
Capex per Share |
(0.20) | (0.21) | (0.16) | (0.07) | |
Capex to Sales |
4.87 | 1.95 | 2.48 | 0.00 | |
Net Profit Margin |
(4,252.89%) | (4,658.63%) | (8,550.65%) | 0.00% |
Columns are period end dates